MMMichele I. Morris

Michele I. Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michele I. Morris has a total of 272 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human antibody repertoire among kidney donors with and without HIV

    by Xianming Zhu, William R. Morgenlander, Diane M. Brown, Yolanda Eby, Megan Morsheimer, Jonah Odim, Serena M. Bagnasco, Meenakshi M. Rana, Sander S. Florman, Rachel J. Friedman-Moraco, et al.

    BACKGROUND: Transplanting kidneys from donors with HIV to recipients with HIV has become standard clinical practice. However, donors with HIV may have higher prevalence of viral and bacterial infections and autoimmunity that could increase allograft rejection in recipients. METHODS: We included deceased kidney donors (60 with HIV and 41 without HIV) who participated in a multicenter prospective study of HIV kidney transplantation between April 2018 and September 2021. Using phage immunoprecipitation sequencing, we compared the human antibody repertoire (allergens, autoantibodies, viruses, and bacterial toxins) between donors with and without HIV and evaluated their association with recipient allograft rejection. Moderated t tests were used to assess reactivity and a multivariate logistic regression model adjusted for donor sex and kidney donor profile index assessed the association between donor adenovirus reactivity and recipient allograft rejection. RESULTS: Compared with donors without HIV, donors with HIV had lower BMI and were more likely to be African American. The median number of positive autoantibodies was marginally higher among donors with HIV (499 [IQR, 357, 579]) compared with that of donors without HIV (395 [IQR, 256, 538], P = 0.058). Donors with HIV additionally had significantly higher antibody reactivity to Epstein-Barr virus and cytomegalovirus ( q < 0.05). Among all donors with and without HIV, antibodies against adenovirus were significantly associated with increased rejection among recipients, including after adjusting for false discovery ( q < 0.05) and also adjusting for demographic factors using multivariable logistic regression (odds ratio = 4.97; 95% CI = 1.89–13.61). CONCLUSION: The presence of antibodies against adenovirus infection in kidney donors with HIV may be associated with allograft rejection. TRIAL REGISTRATION: ClinicalTrials.gov NCT03500315. FUNDING: US NIH.

  • Open Access

    Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era

    by Christopher M. Lopez, Jose F. Suarez, Maria A. Mendoza, Anthony D. Anderson, Jill Lykon, Wenhui Li, Michele I. Morris, Yoichiro Natori, Mohammed Raja, Lazaros J. Lekakis, et al.

    Background: Despite important advancements in diagnostic modalities, routine use of therapeutic drug monitoring (TDM) and newer antifungal therapies, there is a paucity of contemporary data regarding clinical characteristics and outcomes of invasive aspergillosis (IA) in the United States. Methods: Single-center, retrospective cohort study of hospitalized patients between 2015 and 2020, who had active hematological malignancy (HM) or had undergone transplantation and cellular therapy (TCT) and had probable or proven IA. Results: Sixty-two patients with probable or proven IA, including 21 HM and 41 TCT, were identified. Forty-four percent of the cases corresponded to breakthrough IA. Bronchoalveolar lavage galactomannan was ≥ 1 in 71% and ≥ 0.5 in 88%, while serum galactomannan was ≥ 0.5 in only 34%. Among assessable patients (n = 59), 90-day partial or complete response to antifungal therapy occurred in 39%. All-cause mortality for the entire cohort was 22% at 30 days and 46% at 90 days. IA attributable mortality was 18% at 30 days and 38% at 90 days. Achieving therapeutic antifungal serum levels was associated with a reduction in all-cause mortality, while prior clinically significant CMV infection (aOR 9.65, 95% CI 1.34–69.6; P = 0.025) and relapsed/refractory hematological disease (aOR 8.5, 95% CI 2.23, 32.4; P = 0.002) were associated with higher IA attributable mortality. Conclusions: Despite advancements in diagnosis and treatment, IA remains associated with poor outcomes in hematological patients in the contemporary era. Newer antifungals and improved strategies for monitoring and prevention of IA in these vulnerable patient populations are urgently needed.


  • Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV

    by Elizabeth C Arant, Thibaut Davy-Mendez, Tao Liang, Moreno Rodrigues, Cynthia L Gay, Meenakshi M Rana, Rachel Friedman-Moraco, Alexander Gilbert, Peter Stock, Sapna A Mehta, et al.

    Background: Kidney transplantation (KT) from donors with human immunodeficiency virus (HIV-1) to recipients with HIV (HIV D+/R+) is noninferior to KT from donors without HIV (HIV D−/R+) with regard to safety. However, there may be differences in posttransplant infections. Methods: We performed a secondary analysis of the HOPE in Action KT Study (NCT02602262) comparing the time to first clinically relevant infection within 24 months posttransplantation in 99 HIV D+/R+ versus 99 HIV D−/R+. Secondary outcomes included incidence rates, infection-related death, and timing of clinically relevant infection, each stratified by donor HIV status. Results: The cumulative incidence of a clinically relevant infection at 24 months posttransplantation was 73.8% (95% confidence interval [CI]: 63.1%–81.2%) for HIV D+/R+ versus 64.7% (95% CI: 53.0%–73.4%) for HIV D−/R+. Comparing time to first clinically relevant infection in HIV D+/R+ versus HIV D−/R+, the adjusted hazard ratio (aHR) was 1.44 (95% CI: 1.01–2.04) at 24 months posttransplantation; for infections associated with hospitalization, the aHR was not significantly higher (1.21 [95% CI: .78–1.86). There were no significant differences in the number of infections, death from infection, duration, or site of infection between HIV D+/R+ versus HIV D−/R+, though viral infections were numerically more common in HIV D+/R+ (40% vs 35%). Conclusions: Although there was a statistically significant association between receipt of a kidney from a donor with HIV and time to first clinically relevant infection in the 24 months posttransplantation, there were no differences in infections associated with hospitalization. These data are overall reassuring as this emerging practice expands into clinical care. Clinical Trials Registration. NCT02602262.

  • Open Access

    An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant

    by Genovefa A Papanicolaou, Sanjeet S Dadwal, Ella J Ariza-Heredia, Patrizia Chiusolo, Michele I Morris, Eleni Tholouli, Barbara Haber, Natalya Broyde, Christopher L Gilbert, Cyrus Badshah

    Background: Cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) prevents CMV reactivation after hematopoietic cell transplant (HCT). Trends in CMV-CMI using the QuantiFERON-CMV assay and its clinical utility in a Phase 3 study were evaluated. Methods: Cytomegalovirus-seropositive allogeneic HCT recipients who received letermovir prophylaxis through ∼100 days post-HCT were randomized to receive letermovir or placebo through ∼200 days post-HCT. QuantiFERON-CMV was performed at 100 days, 200 days, and Week 48 post-HCT. QuantiFERON-CMV results after prophylaxis completion (∼100 and ∼200 days post-HCT in placebo and letermovir groups, respectively) were evaluated for predicting postprophylaxis clinically significant CMV infection (CS-CMVi) through Week 48 post-HCT. Results: QuantiFERON-CMV assay positivity was similar at study entry between letermovir (n = 82) and placebo (n = 47) groups (30.5% vs 31.9%), higher for placebo group at 200 days post-HCT (48.8% vs 74.5%), and comparable between groups at Week 48 post-HCT (65.9% vs 74.5%). Postprophylaxis CS-CMVi occurred by Week 48 in 10.5% (6/57) of participants with a positive result versus 19.0% (8/42) with a negative result at 200 days post-HCT in the letermovir group and 10.3% (3/29) of participants with a positive result versus 20.7% (6/29) with a negative result at 100 days post-HCT in the placebo group. Assay sensitivity, specificity, positive predictive value, and negative predictive value were 60.0%, 57.1%, 89.5%, and 19.0% for tests at 200 days post-HCT (letermovir) and 53.1%, 66.7%, 89.7%, and 20.7% for tests at 100 days post-HCT (placebo). Conclusions: Positive QuantiFERON-CMV results increased after letermovir prophylaxis completion. Predictive utility of the QuantiFERON-CMV assay may be limited in the HCT setting.


  • Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With Human Immunodeficiency Virus in the United States

    by Puja H Nambiar, Tao Liang, Nazzarena Labo, Jonathan Hand, Emily A Blumberg, Meenakshi M Rana, Sander Florman, Brandy Haydel, Michele I Morris, Joanna Schaenman, et al.

    Background: Due to high prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). Methods: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D–) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD. Results: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D–. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07–2.14] in recipients and 2.39 [95% CI, 1.03–5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D–/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26–1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D–/R+ and were likely recipient KSHV reactivation or acquisition. Conclusions: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.


  • Open Access

    APOL1 genotype and patient outcomes in US and South African transplant recipients with HIV who received kidneys from donors with HIV

    by Robert Freercks, Moreno Rodrigues, Kathryn Manning, Jurgen Heymann, Jeffrey B. Kopp, Savania Nagiah, Meenakshi Rana, Sander Florman, Rachel Friedman-Moraco, Peter Stock, et al.

    Importance: Lower kidney allograft survival has been demonstrated in kidney transplant recipients (KTR) without HIV whose donors have two apolipoprotein L1 ( APOL1 ) renal risk variants (RRV). The effects of APOL1 RRV on kidney transplant outcomes in people with HIV (PWH) have not been fully assessed. Objective: To determine whether APOL1 renal risk variants (G1/G2) in donors or recipients are associated with outcomes of kidney transplantation in people with HIV (PWH)? Design: Comparative analysis of kidney allograft outcomes in two of the largest longitudinal clinical studies examining transplantation outcomes in PWH. Setting and participants: Two cohorts of HIV-positive KTR (R+) and their respective HIV-negative (D-) or HIV-positive (D+) kidney donors from the South African (SA) HIV+ to HIV+ transplantation clinical study and the United States of America (US) HOPE in Action Kidney transplantation clinical trial. All patients with genomic DNA available for APOL1 genotyping were included. APOL1 Genotype was determined using a probe-based assay. Main outcomes measured: Time to first rejection, HIV-associated nephropathy, graft failure or death were compared by both donor and recipient APOL1 RRV status. Results: Genomic DNA was available for 21 donors with HIV and 38 HIV D+/R+ recipients in the SA cohort, and 57 donors (40 D+ and 17 D-) and 119 recipients (49 HIV D+/R+ and 70 D-/R+) in the US cohort. Recipient outcomes were not associated with recipient APOL1 genotype. However, recipients whose donor carried one versus zero APOL1 RRV were significantly more likely to experience a negative composite outcome (pAPOL1 RRV in a donor kidney led to significantly worse post-transplant outcomes while recipient APOL1 genotype was not associated with outcomes. Further research into the interaction between the allograft environment and donor APOL1 genotype in PWH is required. KEY POINTS: Question: Do APOL1 renal risk variants (G1/G2) influence the outcomes of kidney transplantation in people with HIV (PWH)? Findings: In two of the largest cohorts of PWH who are also kidney transplant recipients, the presence of even one donor APOL1 renal risk variant was associated with an adjusted hazard ratio of a poor composite outcome of 10.1 (95%CI=2.4-42.7) and 2.9 (95%CI=1.1-7.4) in the US and SA cohorts, respectively. Recipient APOL1 genotype was not associated with graft outcomes. Meaning: This may have implications for allocation of allograft kidneys in PWH, as well as informing the need for therapies targeting APOL1 gene expression in kidney transplant recipients.


  • Open Access

    Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy

    by Rick Y. Lin, Anthony D. Anderson, Yoichiro Natori, Mohammed Raja, Michele I. Morris, Antonio Jimenez Jimenez, Amer Beitinjaneh, Trent Wang, Mark Goodman, Lazaros Lekakis, et al.

    Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.


  • Open Access

    The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir

    by Sarah E. Benner, Yolanda Eby, Xianming Zhu, Reinaldo E. Fernandez, Eshan U. Patel, Jessica E. Ruff, Feben Habtehyimer, Haley A. Schmidt, Charles S. Kirby, Sarah Hussain, et al.

    The HIV latent viral reservoir (LVR) remains a major challenge in the effort to find a cure for HIV. There is interest in lymphocyte-depleting agents, used in solid organ and bone marrow transplantation to reduce the LVR. This study evaluated the LVR and T cell receptor repertoire in HIV-infected kidney transplant recipients using intact proviral DNA assay and T cell receptor sequencing in patients receiving lymphocyte-depleting or lymphocyte-nondepleting immunosuppression induction therapy. CD4 + T cells and intact and defective provirus frequencies decreased following lymphocyte-depleting induction therapy but rebounded to near baseline levels within 1 year after induction. In contrast, these biomarkers were relatively stable over time in the lymphocyte-nondepleting group. The lymphocyte-depleting group had early TCRβ repertoire turnover and newly detected and expanded clones compared with the lymphocyte-nondepleting group. No differences were observed in TCRβ clonality and repertoire richness between groups. These findings suggest that, even with significant decreases in the overall size of the circulating LVR, the reservoir can be reconstituted in a relatively short period of time. These results, while from a relatively unique population, suggest that curative strategies aimed at depleting the HIV LVR will need to achieve specific and durable levels of HIV-infected T cell depletion.


  • Open Access

    476. A Global Survey of Countermeasures Against the COVID-19 Pandemic Among Solid Organ Transplant Centers

    by Aasith Villavicencio, Mohammed Raja, Deepali Kumar, Lara Danziger-Isakov, Nicole Theodoropoulos, Michele I Morris, Giselle Guerra, Lilian M Abbo, Yoichiro Natori

    Solid organ transplantation (SOT) profoundly impacts vulnerable recipients with chronic end organ diseases. The COVID-19 pandemic disrupted healthcare systems, including organ transplants. We aimed to evaluate the responses of SOT centers to COVID-19 at the beginning of the pandemic around the world. We conducted a web-based survey amongst transplant centers, sent to members of The American Society of Transplantation Infectious Diseases Community of Practice Group, between April and May 2020. The survey included basic information of each transplant center (number and types of transplants in 2019), the countermeasures employed against COVID-19 such as timing of postponing of transplantation, and management of outpatient clinics including implementation of telemedicine and screening for in-person visits. A total of 65 centers from 19 countries responded (Table 1). Regarding the percentage of hospitalized patients with COVID-19 at the time of the survey, 39 (60%) centers reported < 10%, two centers reported > 80%. All centers reduced their services to some extent as shown in Table 2. Centers reported postponing living donor kidney transplant (50/58, 86%), deceased donor kidney transplant (20/57, 35%), living donor liver transplant (32/42, 80%), deceased donor liver transplant (17/41, 41%), lung transplant (20/31, 65%), heart transplant for LVAD (18/33, 55%) and non-LVAD patients (18/33, 55%). In March and April 2020, cancellation of pre- and post- transplant clinics were reported by 36/64 (56%) and 17/65 (26%) centers. Postponing clinic appointments were reported by 56/65 (86%) centers. Most institutions (54/64, 85%) used telemedicine. Screening for COVID-19 for clinic visits was done by telephone, in-person questionnaires and/or temperature checks. During the early phase of the pandemic, when management strategies were highly uncertain, non-urgent and living donor transplants were frequently postponed. Emergent liver transplants continued regardless. These findings could help us navigate SOT in future epidemics. Limitations included a small sample and lack of assessment of clinical outcomes from postponing SOT. Deepali Kumar, MD, MSc, FRCPC, Astellas (Individual(s) Involved: Self): Speakers’ bureau; Atara Biotherapeutics (Individual(s) Involved: Self): Grant/Research Support; GSK (Individual(s) Involved: Self): Consultant, Grant/Research Support; Merck (Individual(s) Involved: Both Myself and my Spouse/Partner): Advisor or Review Panel member, Grant/Research Support; Oxford immunotec (Individual(s) Involved: Self): Consultant, Grant/Research Support; Pfizer (Individual(s) Involved: Self): Speakers’ bureau; Roche (Individual(s) Involved: Self): Consultant, Grant/Research Support; Sanofi (Individual(s) Involved: Self): Advisor or Review Panel member; Shire/Takeda (Individual(s) Involved: Both Myself and my Spouse/Partner): Advisor or Review Panel member, Grant/Research Support Lara Danziger-Isakov, MD, MPH, Ansun (Individual(s) Involved: Self): Scientific Research Study Investigator; Astellas (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Pfizer (Individual(s) Involved: Self): Scientific Research Study Investigator; Shire (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Viracor: Grant/Research Support

  • Open Access

    454. Impact of Covid-19 on Infectious Disease Fellows in the United States: A National Survey to Identify Targets for Intervention

    by Shuba Balan, Shweta Anjan, Alison Ohringer, Jose Gonzales-Zamora, Deborah Jones Weiss, Michele I Morris, Maria L Alcaide, Paola Lichtenberger

    The Coronavirus disease of 2019 (COVID-19) global health crisis has resulted in an unprecedented strain on healthcare systems, reorganization of medical training programs and disruption in professional and personal lives of medical trainees. The impact of COVID-19 on infectious disease (ID) fellows, who are frontline healthcare professionals, has not been assessed. We conducted a national survey of adult and pediatric ID fellows to assess impact on educational activities, availability of personal protective equipment (PPE), well-being, and career prospects. Anxiety and burnout were assessed by 7-item generalized anxiety disorder scale and abbreviated Maslach burnout inventory respectively. Invitations to participate in the survey were sent via email to all ID fellows through Accreditation Council for Graduate Medical Education (ACGME) fellowship directors. Survey responses collected from August 1 to September 30, 2020 have been reported. 136 fellows completed the survey (Table 1). 84% reported their institution had provided evidence-based didactics for management of COVID-19 and 53% indicated their general ID didactics were affected by the pandemic. 86% of fellows were involved in care of patients with COVID-19, and 31% reported a shortage of PPE affecting their clinical duties. Those living in highly impacted states (CA, FL, NY, TX) at the time of the survey were 1.70 times as likely to experience moderate to severe anxiety (vs. minimal to moderate) than those in other states; similarly, those who saw ≥11 COVID-19 patients weekly and reported PPE shortages were 2.5 and 2.0 times as likely, respectively, to experience moderate to severe anxiety compared to their peers who took care of 10 or fewer COVID-19 patients and did not experience PPE shortages. Burnout scores were not significant (Table 2). Table 1. Demographics, Responses to Personal Exposure, Educational Activities and Career Prospects Table 2. Stress, Burnout, Anxiety , Sleep and Quality of Life Among Survey Participants. It is imperative that ID fellows feel adequately protected and supported during this pandemic. Pandemic preparedness should be included in the ID fellowship curriculum. Interventions for anxiety and burnout reduction should be implemented. ID fellowship programs should continue to accept feedback from fellows to ensure their ongoing safety, well-being, and education as we navigate this pandemic. All Authors: No reported disclosures